Evidence map›Paper›PMID 26013710›Full record

ArticleMolecular carcinogenesis2016

Twist1 regulates keratinocyte proliferation and skin tumor promotion.

Jaya Srivastava, Okkyung Rho, Ronnie M Youssef, John DiGiovanni

Open access · greenAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Twist1: A Double-Edged Sword in Kidney Diseases.Kidney diseases (Basel, Switzerland) · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Homeostasis, regeneration and tumour formation in the mammalian epidermis.The International journal of developmental biology · 2018
    Review
  16. Article
  17. Article
  18. Differential BMI1, TWIST1, SNAI2 mRNA expression pattern correlation with malignancy type in a spectrum of common cutaneous malignancies: basal cell carcinoma, squamous cell carcinoma, and melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017
    Article
  19. Variants in an Hdac9 intronic enhancer plasmid impact Twist1 expression in vitro.Mammalian genome : official journal of the International Mammalian Genome Society · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jaya SrivastavaDivision of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas.
Okkyung RhoDivision of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas.
Ronnie M YoussefDivision of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas.
John DiGiovanniDivision of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas.
The University of Texas at Austin · US

Funding

TYROSINE KINASES AND C SRC IN SKIN CANCERR01CA076520 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIGIOVANNI, JOHN · 1998 to 2012
$3.7M
Training in Molecular Toxicology/Environmental DiseaseT32ES007247 · NIEHS · UNIVERSITY OF TEXAS AUSTIN · PI RICHBURG, JOHN H · 1990 to 2014
$2.9M
NCI NIH HHS CA76520NCI NIH HHS R01 CA076520NIEHS NIH HHS ES007247NIEHS NIH HHS T32 ES007247
6 · The paper itself

Abstract

In the present study, we evaluated the effect of deleting Twist1 on keratinocyte proliferation and on skin tumor development using the two-stage chemical carcinogenesis model. BK5.Cre × Twist1(flox/flox) mice, which have a keratinocyte-specific Twist1 knockout (Twist1 KO), developed significantly reduced numbers of papilloma (70% reduction) and squamous cell carcinoma (75% reduction) as well as delayed tumor latency compared to wild-type (WT) mice. Interestingly, knockdown of Twist1 in primary keratinocytes impeded cell cycle progression at the G1/S transition that coincided with reduced levels of the cell cycle proteins c-Myc, Cyclin E1, and E2F1 and increased levels of p53 and p21. Furthermore, ChIP analyses revealed that Twist1 bound to the promoter regions of Cyclin E1, E2F1, and c-Myc at the canonical E-box binding motif suggesting a direct transcriptional regulation. Further analyses of Twist1 KO mice revealed a significant reduction in the number of label-retaining cells as well as the number of α6-integrin(+) /CD34(+) cells in the hair follicles of untreated mice compared to WT mice. These mice also exhibited significantly reduced epidermal proliferation in response to TPA treatment that again correlated with reduced levels of cell cycle regulators and increased levels of p53 and p21. Finally, Twist1 deficiency in keratinocytes led to an upregulation of p53 via its stabilization and nuclear localization, which is responsible for the increased expression of p21 in these cells. Collectively, these findings indicate that Twist1 has a novel role in epithelial carcinogenesis by regulating proliferation of keratinocytes, including keratinocyte stem cells during tumor promotion.

Indexed as

9,10-Dimethyl-1,2-benzanthraceneAnimalsCell CycleCell ProliferationGene Expression Regulation, NeoplasticGene Knockout TechniquesKeratinocytesMiceMice, TransgenicNuclear ProteinsPromoter Regions, GeneticSkin NeoplasmsTetradecanoylphorbol AcetateTwist-Related Protein 19,10-Dimethyl-1,2-benzanthraceneNuclear ProteinsTetradecanoylphorbol AcetateTwist1 protein, mouseTwist-Related Protein 1cell cyclekeratinocyte stem cellsskin carcinogenesisTwist1

Identifiers

PMID26013710
PMCPMC4662634
OpenAlexW2141511457

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.